

**Bilastine in Japan: Phase III trials completed and ready for
registration**

Bilastine has successfully completed two pivotal phase III clinical studies in Japan. These trials, performed in more than 1.000 patients, have shown that bilastine is an effective treatment for allergic rhinitis and urticaria, also for Japanese population.

With this step, bilastine is now ready to proceed with the health registration process in Japan

25 May 2015